Warp and daveludlow, I am an AMBS investor since January

New Post Public Reply Private Reply Replies (2) Message Board
Sidepocket Warp #19323
Warp and daveludlow,

I am an AMBS investor since January 2015. I read 3 years of SEC documents, read back through message boards, listened to some of GC's pod cast, and thought deeply about tying my money up for 1-2 years for a good return and 3-5 years for a boatload. The one thing that sold me on AMBS was the story of GC rescuing his dad's discovery with MANF. It is basically his dad’s lifetime work.

That convinced me that GC was personally invested and would put everything he had into rescuing MANF, and into patients reality.

I don't think the money is GC's goal with this; he grew up in a family with a scientist dad. My guess is he never really wanted for anything. Then he went to Stanford, played football, and spent 3 years in the USFL. I think GC has all the money he needed to do pretty much what he wanted. All he does is work, never heard of any partying or risky behavior. He is proving to his dad that he can carry on “his” dream. That’s why I became an AMBS investor.

Now daveludlo, I also agree with most of your argument that GC said or insinuated that many goals would be meet by 4th quarter 2014 and 1st quarter 2015. I agree that to some extent, he went out and sold AMBS with all his heart even if somewhat, not exaggerated or lying, but with a deep down belief that he could pull off the best case scenario. Yes, he had a very risky timeline for hitting some lofty and goals within a very short time. And, he didn't hit them all.

But he did hit some, and he scored some new potential to cover the gap.

But clearly GC and the BODs new that if he couldn’t hit the timeline and find a partner for DX then he would need to finance it through dilution. It was AMBS’s safety net.

All the SEC documents that discuss forward-looking statements said that dilution would probably be required to keep AMBS in business. So anybody that studied the company new that it was highly probable that AMBS would have to sell some of the 1B new shares that the shareholders approved in September 2014.

So in my opinion, GC didn’t lie, he just couldn’t execute his best-case plan. Even with his polished speaking and his heart behind it. So please Dave, let go of the bashing of the CEO of our mutual stock. Continue to articulate the facts of his performance, but believe that his heart is with the company and he is doing his best, even if it’s a little ambitious.

Then the dilution came to pay off the lawsuit, the ESS kick-off, hire new people, Elto Phase2b, and other payments due. Along with that, I am sure the sell of stock by some of the people receiving shares for accounts receivable, the financer, and others. Not to mention the fear shareholders had knowing the dilution was coming but not knowing how much. People panicked and the PPS got hammered. But, as of the today with the new share count the market cap was back to $52M. Don’t bet on ithis being the last time the PPS gets hammered for a short time, it will again.

So Warp, I think I could predict 4 positive milestones that may be hit by the end of June 2015. I have no idea about the PPS though. For me, dilution is going to be a bedfellow for a while and the panic factor of shareholders will be hard to nail down.

Warp and davelulow, my point is this. We are all at least somewhat intelligent and can articulate our thoughts. So how about cut out the monotonous fighting and reporting about the “other” board and participate in some adult investing conversation. And Warp, I do enjoy watching the day-to-day life of AMBS. It is a part of my life now for the foreseeable future. It is now a family member. So I do enjoy thinking through what’s going on, discussing the milestones, timing, problems, setbacks, dilution, leadership, the markets impact and a 1,000 other related subjects about AMBS. And davedulow, I don’t mind discussing the failures, just in a civil manner.

So both of you, please join me…

Amarantus Bioscience Holdings (AMBS) Stock Research Links

AMBS Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Workhorse Group Battles Nasdaq Compliance Amid Financial Woes

Updated Category News Views 87

Workhorse Group Faces Nasdaq Compliance Challenges Workhorse Group Inc (NASDAQ: WKHS), a manufacturer in the electric vehicle sector, has recently been issued a notice by the Nasdaq Stock Market regarding its non-compliance with the minimum bid price requirement. The pressing issue arises from the company's common stock trading below the $1.00 mark for a continuous period...

Continue Reading
Investors Have a Deadline to Join NET Power Class Action

Updated Category News Views 293

Investors Have a Deadline to Join NET Power Class Action In a significant turn of events, Kahn Swick & Foti, LLC advises investors who’ve incurred losses exceeding $100,000 in NET Power Inc. to take action. If you are among those affected, the time is critical. You have until June 17, 2025 to file your lead plaintiff application in this securities class action lawsuit...

Continue Reading
New Developments in Borregaard ASA's Share Transactions

Updated Category News Views 152

Insight into Recent Share Purchases at Borregaard ASA Recently, significant transactions have emerged within Borregaard ASA that are noteworthy for investors and stakeholders alike. Tove Andersen, a dedicated member of the board, made headlines by acquiring 2,000 shares at a price of NOK 187.92 each. This purchase marks a decisive move, increasing her total holdings to...

Continue Reading
Guaranteed Roof Enhances Commercial Roofing Options in NC

Updated Category News Views 136

Guaranteed Roof Enhances Commercial Roofing Options in North Carolina Guaranteed Roof, recognized for its expertise in roof rejuvenation and replacement services, is excited to announce a major enhancement to its commercial division. This initiative strongly emphasizes the utilization of FAR Coatings, a cutting-edge solution for flat and low-slope roofs. By leveraging...

Continue Reading
Key Details for Sage Therapeutics, Inc. Investors Ahead of Deadline

Updated Category News Views 38

Understanding the Class Action for Sage Therapeutics, Inc. As a diligent investor, knowing your rights is crucial, especially when involved with companies like Sage Therapeutics, Inc. (NASDAQ: SAGE). If you purchased securities between specific dates, it’s essential to pay attention to upcoming deadlines. The Importance of the Deadline The Rosen Law Firm, a leading...

Continue Reading